Wolters Kluwer to Divest Its Pharma Solutions Business

7/27/2011, 8:01 AM (Source: GlobeNewswire)
Strategy to Focus on Core Health Markets in Content and Clinical Decision
Support Solutions Globally

Alphen aan den Rijn, the Netherlands (July 27, 2011) - Wolters Kluwer, a market
leader in the professional health content and clinical decision support market,
today announced a plan to divest its pharma business. The company is well-
positioned to benefit from healthcare reform trends globally to support the
Health division's growth strategy.

"The planned divestment of the pharma business will focus our Health division on
taking full advantage of our leading positions in professional information and
clinical decision support solutions, one of the fastest growing areas of Health,
to deliver enhanced value to our stakeholders," said Nancy McKinstry, CEO and
Chairman of the Executive Board of Wolters Kluwer.

The pharma business, with leading brands Source and Adis, provides marketing and
publications services, business intelligence products, and advanced analytical
tools and services to support life sciences professionals from discovery through
development and distribution.

"The pharma business delivers great value to our pharmaceutical, biotech and
medical device customers globally," said Bob Becker, President & CEO of Wolters
Kluwer Health & Pharma Solutions. "Moving forward, we are excited about
continued opportunities to deliver value to global customers through our
portfolio of leading brands in content and clinical decision support, which are
well-positioned to benefit from healthcare reform trends globally to support the
division's growth strategy."

Wolters Kluwer Health & Pharma Solutions is a global provider of information,
business intelligence and point-of-care solutions for the healthcare industry,
with leading brands including Lippincott Williams & Wilkins, Ovid(®), Pharmacy
OneSource(®), Lexicomp and UpToDate(®), among others. Its customers include
professionals, students, institutions and organizations across the globe.
Products and services include industry-leading textbooks and journals,
electronic drug data and clinical information, electronic medical, scientific
and academic research solutions, clinical decision support solutions and
evidence-based content that is easily accessible at the point of care.

The company expects the planned divestiture to close around or shortly after the
end of the year. Lazard Middle Market and William Blair & Company are acting as
financial advisors to Wolters Kluwer Health & Pharma Solutions for the planned

For more information on Wolters Kluwer Health, visit
www.wolterskluwerhealth.com. For more information on Pharma Solutions, visit

About Wolters Kluwer
Wolters Kluwer is a market-leading global information services company.
Professionals in the areas of legal, business, tax, accounting, finance, audit,
risk, compliance, and healthcare rely on Wolters Kluwer's leading information-
enabled tools and software solutions to manage their business efficiently,
deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer had 2010 annual revenues of €3.6 billion, employs approximately
19,000 people worldwide, and maintains operations across Europe, North America,
Asia Pacific, and Latin America, serving customers globally. Wolters Kluwer is
headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on
Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.

Visit our website, YouTube, follow @Wolters_Kluwer on Twitter, or look up
Wolters Kluwer on Facebook for more for information about our customers, market
positions, brands, and organization.

Should you wish to change how you receive information from Wolters Kluwer,
please click here.

Forward-looking Statements
This press release contains forward-looking statements. These statements may be
identified by words such as "expect", "should", "could", "shall", and similar
expressions. Wolters Kluwer cautions that such forward-looking statements are
qualified by certain risks and uncertainties that could cause actual results and
events to differ materially from what is contemplated by the forward-looking
statements. Factors which could cause actual results to differ from these
forward-looking statements may include, without limitation, general economic
conditions; conditions in the markets in which Wolters Kluwer is engaged;
behavior of customers, suppliers, and competitors; technological developments;
the implementation and execution of new ICT systems or outsourcing; and legal,
tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as
risks related to mergers, acquisitions, and divestments. In addition, financial
risks such as currency movements, interest rate fluctuations, liquidity, and
credit risks could influence future results. The foregoing list of factors
should not be construed as exhaustive. Wolters Kluwer disclaims any intention or
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.

Contact: Caroline Wouters Robert Dekker Jon Teppo
Vice President, Vice President, Vice President,
Corporate Communications Investor Relations
Communications Wolters Kluwer Wolters Kluwer
Wolters Kluwer Health & Pharma Solutions + 31 (0)172 641 407
+ 31 (0)172 641 459 +1 (215) 521 8928 ir@wolterskluwer.com
press@wolterskluwer.com robert.dekker@wolterskluwer.com

PDF version of Press Release:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Wolters Kluwer NV via Thomson Reuters ONE

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.